Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

AIM: To estimate the cost‐effectiveness of sequential addition of empagliflozin versus sitagliptin after metformin in patients with type 2 diabetes (T2D) with or without cardiovascular disease (CVD) from the perspective of the US healthcare payer. METHODS: An individual simulation model predicted li...

Descripción completa

Detalles Bibliográficos
Autores principales: Reifsnider, Odette, Kansal, Anuraag, Pimple, Pratik, Aponte‐Ribero, Valerie, Brand, Sarah, Shetty, Sharash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898389/
https://www.ncbi.nlm.nih.gov/pubmed/33236481
http://dx.doi.org/10.1111/dom.14268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898389/
https://www.ncbi.nlm.nih.gov/pubmed/33236481
http://dx.doi.org/10.1111/dom.14268

Ejemplares similares